Copyright
©The Author(s) 2015.
World J Gastroenterol. Jul 7, 2015; 21(25): 7754-7763
Published online Jul 7, 2015. doi: 10.3748/wjg.v21.i25.7754
Published online Jul 7, 2015. doi: 10.3748/wjg.v21.i25.7754
Figure 1 Ezetimibe improves hepatic steatosis in OLETF rats.
A: Representative HE liver sections (scale bar, 200 μm; magnification × 200); B: NAFLD activity score. Data are expressed as the mean ± SE. aP < 0.05 vs OLETF control. ND: Not detected in LETO control (LETO con); white bar: OLETF control (OLETF con); black bar: OLETF ezetimibe group (OLETF Ez); NAFLD: Nonalcoholic fatty liver disease.
- Citation: Chang E, Kim L, Park SE, Rhee EJ, Lee WY, Oh KW, Park SW, Park CY. Ezetimibe improves hepatic steatosis in relation to autophagy in obese and diabetic rats. World J Gastroenterol 2015; 21(25): 7754-7763
- URL: https://www.wjgnet.com/1007-9327/full/v21/i25/7754.htm
- DOI: https://dx.doi.org/10.3748/wjg.v21.i25.7754